

Biol Ther (2014) 4:81  
DOI 10.1007/s13554-014-0020-6

---

**ERRATUM**

## Erratum to: Switching to Omnitrope® from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System

Nazia Rashid · Paul Saenger · Yi-Lin Wu · Heike Woehling ·  
Matthew Frankel · Fima Lifshitz · Michael Muenzberg · Robert Rapaport

To view enhanced content go to [www.biologicstherapy-open.com](http://www.biologicstherapy-open.com)  
Published online: November 19, 2014  
© The Author(s) 2014. This article is published with open access at [Springerlink.com](http://Springerlink.com)

Erratum to: Biol Ther 4(1–2) (2014)  
DOI 10.1007/s13554-014-0017-1

The authors of the above-mentioned paper noticed some errors subsequent to publication and would like to make the following corrections.

On pages 5 and 6, Table 1 will include a footnote for the prior non-Omnitrope rhGH therapy: “These patients are not mutually exclusive, they could have been on multiple GH therapies prior to switching to Omnitrope”.

On page 10 under the heading Discussion the recommended dose of GH therapy in TS

patients pre- and post-switch should be 0.33 mg/kg/week. The sentence should now read “We recognize that the GH therapy dose that was used in TS patients pre- and post-switch was less than the recommended dose of 0.33 mg/kg/week”.

**Open Access.** This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

---

The online version of the original article can be found under doi:[10.1007/s13554-014-0017-1](https://doi.org/10.1007/s13554-014-0017-1).

---

N. Rashid (✉)  
Kaiser Permanente, Southern California Region,  
Drug Information Services, Downey, CA, USA  
e-mail: [Nazia.X.Rashid@kp.org](mailto:Nazia.X.Rashid@kp.org)

P. Saenger  
Department of Pediatrics, Albert Einstein College  
of Medicine, New York, NY, USA

Y.-L. Wu  
Department of Research and Evaluation, Kaiser  
Permanente, Pasadena, CA, USA

H. Woehling · M. Muenzberg  
Sandoz International GmbH, Holzkirchen, Germany

M. Frankel  
Sandoz Inc., Princeton, NJ, USA

F. Lifshitz  
Pediatric Sunshine Academics, Santa Barbara,  
CA, USA

R. Rapaport  
Department of Pediatrics, Mount Sinai College  
of Medicine, New York, NY, USA